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Varicella zoster virus in the adult patient most commonly presents as shingles. Shingles is a 
painful vesicular eruption localized to a specific dermatome of the body. One of the potential 
complications of this infection is involvement of the central nervous system causing encephalitis. 
An increased risk of this complication is associated with the immunocompromised patient. In this 
case report, we review the history and physical exam findings that should raise clinical suspicion 
for varicella zoster encephalitis, as well as the epidemiology, risk factors, treatment, and prognosis 
of this type of infection. [Clin Pract Cases Emerg Med. 2019;3(4):380–382.]
INTRODUCTION
We present a case of a patient with varicella zoster virus 
(VZV) encephalitis caused by a combination of the patient 
having active virus reactivation in the form of shingles on 
the right leg, in addition to being immunocompromised 
due to a kidney transplant. According to the World Health 
Organization, encephalitis occurs in one out of every 
33,000–50,000 cases of VZV. It also carries a less favorable 
prognosis compared to the other extracutaneous complications 
of VZV. This case report shows how prompt recognition 
and treatment of this type of infection can decrease 
mortality and progression of the infection in the high-risk, 
immunocompromised patient.
CASE REPORT
A 67-year-old man with a medical history of kidney 
transplant, chronic renal dysfunction, prior cytomegalovirus 
infection causing retinal damage and vision loss and 
prescribed valacyclovir presented to the emergency 
department (ED) with a complaint of hallucinations and 
weakness. This was the patient’s fifth healthcare encounter 
in three weeks. The first visit was to the ED for heel pain, 
and he was discharged home after an unremarkable right foot 
radiograph. The patient then returned to the ED for his second 
visit with a painful vesicular rash along the second sacral 
dermatome of his right leg and was prescribed valacyclovir 
1 gram orally three times a day for seven days for shingles. 
Vaccination status was unknown at the time of diagnosis. 
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On the third ED visit two days later, the patient presented 
with vomiting after being seen by his primary care doctor 
that morning. The patient was able to tolerate two doses of 
valacyclovir; and while being seen by his primary care doctor, 
his valacyclovir dosing was adjusted to account for his renal 
disease. The patient also was experiencing hallucinations but 
was discharged home with the explanation that his symptoms 
could have been due to dehydration after a “negative workup.” 
On his fourth visit to the ED seven days later, the patient 
stated that he would “close his eyes and see bands playing 
and rolling plains of green grass.” He stated that these images 
were very vivid but would go away when he opened his eyes. 
The patient also had difficulty ambulating and generalized 
weakness. A family member reported that he also had 
difficulty with finding words.  
Vital signs during this fourth ED visit included the 
following: temperature 99.4° Fahrenheit; pulse 92 beats per 
minute; respiratory rate 20 respirations per minute; room air 
pulse oximetry 98%, and a blood pressure of 196/91 millimeters 
of mercury. Physical examination revealed crusted lesions 
following the second sacral dermatome on the posterior right 
leg extending from the sacral region to the lower calf. A 
neurological exam revealed generalized weakness and difficulty 
with ambulation without any focal deficits.
Laboratory testing, including complete blood count, 
metabolic panel and urinalysis were unremarkable except 
for serum blood urea nitrogen, creatinine and glomerular 
filtration rate, which were 23.1 milligrams per deciliter (mg/
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What do we already know about this clinical 
entity? 
Varicella Zoster Virus (VZV) affects approximately 
30% of people in the United States. Encephalitis 
carries a less favorable prognosis compared to 
other extra-cutaneous complications of VZV.
What makes this presentation of disease 
reportable? 
Emergency physicians are not suspicious of VZV 
encephalitis as a possible cause in elderly patients 
with altered mental status. This presentation raises 
awareness of the importance of considering VZV 
encephalitis in these patients.
What is the major learning point? 
Keep a high index of suspicion for VZV 
encephalitis in the elderly population and those 
that are immunocompromised, especially with a 
recent history of rash. 
How might this improve emergency medicine 
practice? 
Presenting this case and raising awareness amongst 
emergency physicians can help prevent a delay in 
diagnosis and improve outcomes.
dL) (normal range 6.0-20.0 mg/dL), 3.03 mg/dL (normal 
range 0.67-1.17 mg/dL) and 22 milliliters per minute (mL/
min) (normal is  >60 mL/min), respectively. Chest radiograph 
was unremarkable and brain computed tomography (CT)
demonstrated only chronic mild to moderate degenerative 
changes. Based on the recent diagnosis of shingles, history 
of immunocompromise and hallucinations with weakness, 
lumbar puncture was performed. Results included elevated 
protein with lymphocyte predominance consistent with viral 
infection. Cerebral spinal fluid (CSF) culture was ordered, 
and the patient was administered one gram of acyclovir 
intravenously and admitted to the hospital. 
On hospital day one CSF culture demonstrated VZV via 
polymerase chain reaction (PCR). The patient also underwent 
brain magnetic resonance imaging (MRI) on hospital day 
two, which showed moderate chronic microvascular ischemia 
and abnormal appearance of the distal left vertebral artery. 
Infectious disease, neurology and hospital medicine teams all 
evaluated the patient and agreed with the diagnosis of VZV 
encephalitis in the setting of recent shingles, CSF findings, 
and patient presentation. The patient was administered a 
two-week course of acyclovir with improvement of his 
hallucinations and presenting symptoms prior to discharge on 
hospital day four.
DISCUSSION
VZV affects approximately 30% of people in the United 
States during their lifetime.1 Primary infection causes 
chickenpox or varicella. The virus is never fully eradicated 
from the body, however, as it travels and lies dormant in 
the cranial, dorsal root, or autonomic ganglion.2 Secondary 
VZV skin eruption demonstrates a characteristic unilateral, 
vesicular, and painful eruption that follows a distinct 
dermatomal distribution. The typical pain pattern of the virus 
is caused by increased excitability of central nociceptors in 
the spinal cord causing inflammation and disruption to the 
nerve cells, making them more sensitive to painful stimuli.3
VZV can also cause many different central nervous 
system (CNS) pathologies if the infection invades the spinal 
cord or cerebral arteries, including cerebellar ataxia, arteritis, 
myelitis, meningitis, and encephalitis. CNS infection can 
occur with primary or secondary reactivation of the virus. 
Two main risk factors increase the risk for VZV, including 
age greater than 50 years old and immunocompromise due 
to reduced T cell-mediated immunity.4 Transplant patients 
are at increased risk compared to the general public with an 
incidence rate of 17:1000.5 The patient in this case study had 
both of these main risk factors.
VZV encephalitis causes a headache, fever, vomiting, 
and altered level of consciousness or even seizures. The 
patient in this case presented with vomiting, mental status 
changes, and hallucinations. These symptoms can be seen 
more commonly as side effects due to inappropriately 
renal-dosed valacyclovir. VZV encephalitis mortality rate 
for immunocompetent patients is approximately 15% and 
almost 100% in an immunosuppressed patient, especially 
if both the liver and lung are infected.1,6 VZV encephalitis 
CSF analysis typically demonstrates lymphocytic 
pleocytosis and elevation of protein both of which occurred 
in this case. Positive PCR testing in CSF confirms VZV.7 
CSF anti-VZV antibodies can be performed but cannot 
be used alone as means for diagnosis of VZV-related 
neurological conditions.2,8
Common findings on brain CT specific for VZV 
encephalitis are a hypodensity in the temporal lobes with 
possible frontal lobe involvement. The basal ganglia are 
commonly spared. For MRI, the common findings for VZV 
encephalitis are edematous changes with hyperdensity in 
the temporal lobes and inferior frontal lobes with the basal 
ganglia being spared.9,10 
Treatment of VZV encephalitis is intravenous (IV) 
acyclovir for seven days in the immunocompetent patient 
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and 10-14 days in the immunosuppressed patient. The 
patient, in this case, received IV acyclovir for four days 
and was discharged on two-week course of oral acyclovir. 
Steroids can be used to reduce inflammation if there is 
concern for vasculopathy.11 The valacyclovir initially 
prescribed was discontinued by the patient after only 
two doses due to vomiting. Had the patient taken the full 
course of medication, neurologic side effects due to renal 
impairment could have been a cause for his presentation. 
The incidence of positive PCR CSF in immunosuppressed 
patients with shingles alone is unknown. 
CONCLUSION
The presence of vomiting, hallucinations, and 
mental status changes should alert the emergency 
physician to consider VZV encephalitis, especially in the 
immunocompromised patient. Prompt lumbar puncture 
and early administration of IV acyclovir are critical. Also, 
antiviral medications may cause adverse neurologic effects, 
especially in older patients with renal disease.
Documented patient informed consent and/or Institutional Review 
Board approval has been obtained and filed for publication of this 
case report.
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